key: cord-0034740-7meqqbhu authors: nan title: The development of antimicrobial agents, past, present and future date: 2005 journal: Biochemistry and Molecular Biology of Antimicrobial Drug Action DOI: 10.1007/0-387-27566-5_1 sha: 03e50f0418678d4541ab194dd50c46baa0ab2648 doc_id: 34740 cord_uid: 7meqqbhu nan Few developments in the history of medicine have had such a profound effect upon human life and society as the development of the power to control infections by micro-organisms. In 1969 the Surgeon General of the United States stated that it was time 'to close the book on infectious diseases'. His optimism, which was then shared by many, seemed justified at the time. In the fight against infectious disease, several factors had combined to produce remarkable achievements. The first advances were mainly the result of improved sanitation and housing. These removed some of the worst foci of infectious disease and limited the spread of infection ttaough vemiin and insect parasites or by contaminated water and food. The earliest effective direct control of infectious diseases was achieved through vaccination and similar immunological methods which still play an important part in the control of infection today. The use of antimicrobial drugs for the control of infection was almost entirely a development of the twentieth century, and the most dramatic developments have taken place only since the 1930s. Surgery is no longer the desperate gamble with human life it had been in the early nineteenth century. By the late nineteenth century, the perils of childbirth had been greatly lessened with the control of puerperal fever. The death of children and young adults from meningitis, tuberculosis and septicemia, once commonplace, was, by the late 1960s, unusual in the developed world. Unfoituoately, since the heady optimism of the 1960s we have learned to our cost that microbial pathogens still have the capacity to spring unpleasant surprises on the world. The problem of acquired bacterial resistance to drugs, recognized since the very beginning of antimicrobial chemotherapy, has become ever more menacing. Infections caused by the tubercle bacillus and Staphylococcus aureus, which were once readily cured by drug therapy, are now increasingly difficult or even impossible to treat because of widespread bacterial resistance to the available drugs. Nor is resistance confined to these organisms; many other species of bacteria as well as fungal pathogens, viruses and protozoa, have also become drug-resistant. The ability of micro-organisms to kill or disable the more vulnerable members of society, especially the very young and old and patients with weakened immune defences, is reported io the media almost daily. Alarming reports of lethal enteric infections, meningitis and 'flesh-eatiog' bacteria have become depressingly familiar. If this were not enough, the spectre of the virus (HIV) infection which leads to AIDS (acquired immune deficiency syndrome) threatens human populations around the world, in nations both rich and poor. Drug therapy for AIDS can, initially at least, be very effective, but for the occasional outbreaks of terrifying viral infections such as Ebola and Lassa fever, there are no treatments,. Perhaps more worrying than these sporadic African hemorrahgic fevers, however, is the perceived risk of epidemic or pandemic infections caused by the recently discovered severe acute respiratory syndrome (SARS) vims, or novel recombinations of highly virulent influenza viruses with the potential for causing severe illness and death on a catastrophic scale. In recent years the mosquito-bome West Nile virus, which in some cases can cause a potentially fatal encephalitis, has been the subject of increasing concern in North America. Throughout much of the tropical and subtropical world, malaria continues to exact a dreadful toll on the health and lives of inhabitants. Although mass movements of populations and the failure to control the anophelene mosquito insect vector are major factors in the prevalence of malaria, the increasing resistance of the malarial protozoal parasite to drag treatment is of the greatest concern. Thirty years ago serious infections caused by fungi were relatively rare. More common infections like thrash and ringworm were more of an unpleasant nuisance than a serious threat to health. Today, however, many patients with impaired immunity caused by HIV infection, cytotoxic chemotherapy for malignant disease, or the immunosuppressive treatment associated with organ graft surgery, are at risk from dangerous fungal pathogens such as Pneumocystis carinii and Cryptococcus neoformans. Less viralent organisms like Candida albicans can also be devastating in immunocompromised patients. Inevitably, the increasing use of antifungal drugs to control these infections results in the emergence of drug-resistant pathogens. Fortunately, despite the threats posed by dragresistant bacteria, virases, protozoal parasites and fungal pathogens, the current scene is not one of unrelieved gloom. Most bacterial and fungal infections can still be treated successfully with the remarkable array of drugs available to the medical (and veterinary) professions. Work continues to develop drags effective against resistant pathogens, and there has been major progress against virases causing AIDS, influenza and herpes infections. Vaccines are remarkably successful in preventing some bacterial and viral infections. Indeed, outstanding amongst the medical achievements of the twentieth century was the eradication of smallpox and the dramatic reduction in the incidence of poliomyelitis through mass vaccination programmes. A further incentive to the discovery and development of novel antimicrobial drugs and vaccines is the threat of bioterorrism, which could exploit conventional lethal pathogens such as anthrax and smallpox or even micro-organisms genetically manipulated to extraordinary levels of virulence and drag resistance. Finally, mention must be made of the recent and unexpected emergence of infectious prions which are associated with such devastating neurological pathologies as Creuzfeldt-Jacob disease (CJD) and new variant CJD, or mad cow disease in humans. It is now almost universally accepted that the heat and chemically resistant prion particles are proteinaceous and contain no detectable nucleic acid-encoded information. Infection is transmitted by various routes, including oral ingestion, for example, in contaminated food, by injection, or during surgery and possibly by blood transfusion. At present there is no effective drag treatment to arrest or delay the relentless progression of the infection, which involves the conversion of a normal neuronal protein of unknown function to an insoluble and newly infectious form through interaction with the invading, closely related prion protein. The disturbing possibility of a slowly developing epidemic of newvariant CJD is spurring efforts to find drags or vaccines to control prion infections. 1.2 An outline of the historical development of antimicrobial agents 1.2.1 Early remedies Among many traditional and folk remedies, three sources of antimicrobial compounds have survived to the present day. These are cinchona bark and Artemisia annua (Chinese quing hao su) for the treatment of malaria and ipecacuanha root for amebic dysentery. Cinchona bark was used by the Indians of Peru for treating malaria and was introduced into European medicine by the Spanish in the early seventeenth century. The active principle, quinine, was isolated in 1820. Quinine remained the only treatment for malaria until well into the twentieth century and still has a place in chemotherapy. The isolation of artemisinin, the active compound in Artemisia annua, by Chinese scientists is much more recent and only in recent years has its therapeutic potential against malaria been fully appreciated. Ipecacuanha root was known in Brazil and probably in Asia for its curative action in diarrheas and dysentery. Emetine was isolated as the active constituent in 1817 and was shown in 1891 to have a specific action against amebic dysentery. In combination with other drugs, it is still used for treating this disease. These early remedies were used without any understanding of the nature of the diseases. Malaria, for example, was thought to be caused by 'bad air' (mal'aria) arising from marshy places; the significance of the blood-borne parasite was not recognized until 1880, and only in 1897 was the anophelene mosquito proved to be the specific insect vector when the developing parasite was observed in the intestine of the mosquito. The use of disinfectants and antiseptics also preceded an understanding of their action, and seems to have arisen from the obsen'ation that certain substances stopped the putrefaction of meat or the rotting of wood. The temi 'antiseptic' itself was appai^ently first used by Pringle in 1750 to describe substances that prevent putrefaction. The idea was eventually applied to the treatment of suppurating wounds. Mercuric chloride was used by Arabian physicians in the Middle Ages to prevent sepsis in open wounds. However, it was not until the nineteenth century that antiseptics came into general use in medicine. Chlorinated soda, essentially hypochlorite, was introduced in 1825 by Labarraque for the treatment of infected wounds, and tincture of iodine was first used in 18.39. One of the earliest examples of disinfection used in preventing the spread of infectious disease was recorded by Oliver Wendell Holmes in 1835. He regularly washed his hands in a solution of chloride of lime when dealing with cases of puerperal fever and thereby greatly reduced the incidence of fresh infections, as did Ignaz Semmelweiss in Vienna a few years later. These pioneer attempts at antisepsis were not generally accepted until Pasteur's publication in 1863 identifying the microbial origin of putrefaction. This led to an under-standing of the origin of infection and suggested the rationale for its prevention. As so often in the history of medicine, a change in practice depended upon the personality and persistence of one man. In antiseptics this man was Lister. He chose phenol, the antiseptic which had been introduced by Lemaire in 1860, and applied it vigorously in surgery. A 2.5% solution was used for dressing wounds and twice this concentration for sterilizing instruments. Later he used a spray of phenol solution to produce an essentially sterile environment for canying out surgical operations. The previous state of surgery had been deplorable; wounds usually became infected and the mortality was appalling. The effect of Lister's measures was revolutionary, and the antiseptic technique opened the way to great surgical advances. Even at this time, about 1870, the use of antiseptics was still empirical. An understanding of their function began with the work of Koch, who from 1881 onwards introduced the techniques on which modem bacteriology has been built. He perfected methods of obtaining pure cultures of bacteria and growing them on solid media, and he demonstrated practical methods of sterile working. Once it became possible to handle bacteria in a controlled environment, the action of disinfectants and antiseptics could be studied. The pioneer work on the scientific approach to this subject was published by Kronig and Paul in 1897. Since that time, the history of antiseptics has been one of steady but unspectacular improvement. Many of the traditional antiseptics have continued in use in refined fomis. The phenols have been modified and made more acceptable for general use. Acriflavine, introduced in 1913, was the first of a number of basic antiseptics. It had many years of use but was displaced by colourless cationic antiseptics and the non-ionic triclosan (acriflavine is bright orange). In surgery the antiseptic era gave way to the aseptic era in which the emphasis is on the avoidance of bacterial contamination rather than on killing bacteria already present. All the same, infection of surgical wounds remains a constant risk and antiseptics are still used as an extra precaution or second line of defence. Surgical staff also 'scrub up' with mild antiseptic solutions before entering the operating theatre. Disinfectants play an important pait in the hygiene of milking sheds, broiler houses and other places where strict asepsis is impracticable. The publications of Pasteur and Koch firmly established that micro-organisms are the cause of infectious disease, though for some diseases the causative organisms still remained to be discovered. It was also known that bacteria are killed by various antiseptics and disinfectants. Not surprisingly, attempts were made to kill micro-organisms within the body and so end the infection. Koch himself carried out some experiments with this aim. He had shown that mercuric chloride is one of the few disinfectants that kill the particularly tough spores of the anthrax bacillus. Koch therefore tried to cure animals of anthrax infection by injecting them with mercuric chloride. Unfortunately the animals died of mercury poisoning and their organs still contained infectious anthrax bacilli. A slightly more successful attempt to cure an infection with a toxic agent was made by Lindgard in 1893. He treated horses suffering from surra, a disease now known to be caused by trypanosomes, with arsenious oxide. There was some improvement of the disease, but the compound was too toxic to be generally useful. Chemotherapy, however, really began with Paul Ehrlich. During the ten years from 1902 onwards Ehrlich's work foreshadowed many of the concepts which have governed subsequent work on antimicrobial agents. His first ideas arose from studies with 'vital stains', dyestuffs that were taken up selectively by living tissue. One such dye was methylene blue, which in the animal body is concentrated in nervous tissue. Ehrlich showed that the same dye is readily taken up by malaria parasites in the blood so that they become deeply stained. Consequently methylene blue was tried against human malaria and showed some effect, though not sufficient to make it a useful treatment. Nevertheless, this minor success started a line of thought that was to prove of the greatest significance. Ehrlich believed that antimicrobial agents must be essentially toxic compounds and that they must bind to the micro-organism in order to exert their action. The problem was to discover compounds having a selective action against the microbial cell rather than the cells of the host animal. Starting from methylene blue, Ehrlich began to search for other dyestuffs that would affect protozoal diseases. In 1904, after testing hundreds of available dyes, he eventually found one that was effec-tive against trypanosomiasis in horses. This compound, called trypan red, was a significant landmark in the treatment of microbial infections since it was the first man-made compound that produced a curative effect. However, it was not in the field of dyestuffs that Ehrlich achieved his greatest success. Following the early work on the treatment of trypanosomiasis with arsenious oxide, Koch tested the organic arsenical, atoxyl (Figure 1.1 ). This compound produced the first cures of sleeping sickness, a human trypanosomal disease. Unfortunately, however, the compound produced serious side effects, with some patients developing optic atrophy. The curative effect of this compound stimulated Ehrlich to make other related arsenicals. He tested these on mice infected experimentally with trypanosomiasis and showed that curative action did not parallel toxicity to the mice. This suggested that if enough compounds were made, some would have sufficiently low toxicity to be safe as chemotherapeutic agents. Elhrlich continued his search for compounds active against various micro-organisms and showed that arsenicals were active against the causative organism of syphilis. He began a massive search for an organoarsenical compound that could be used in the treatment of this disease and eventually in 1910 discovered the famous drug salvarsan (Figure 1 .1). This dmg and its derivative, Neosalvarsaii, became the standard treatment for syphilis. Coupled with bismuth therapy, they remained in use until supplanted by penicillin in 1945. This was the most spectacular practical achievement of Ehrlich's career, but scientifically he is remembered at least as much for his wealth of ideas that have inspired workers in the field of chemotherapy down to the present day. These ideas are so important that they deserve separate consideration. The very term 'chemotherapy' was invented by Ehrlich and expressed his belief that infectious disease could be controlled by treatment with synthetic chemicals. Successes since his day have entirely justified his faith in this possibility. He postulated that cells possess chemical receptors which are concerned with the uptake of nutrients. Drugs that affect the cell must bind to one or other of these receptors. The toxicity of a drug is determined partly by its distribution in the body. However, in the treatment of an infection, the binding to the parasite relative to the host cell determines the effectiveness of the compound. Thus Ehrlich recognized the importance of Cjuantitative measurement of the relationship between the dose of a compound recjuired to produce a therapeutic effect and the dose that causes toxic reactions. Such measurements are still of prime importance in chemotherapy today. Ehrlich pioneered methods that have since become a mainstay of the search for new drugs. One aspect of his approach was the use of screening. This is the application of a relatively simple test to large numbers of compounds in order to obtain evidence of biological activity in types of chemical structure not previously examined. Modern drug-discovery laboratories usually employ sequences or cascades of screening tests, often beginning with a purified enzyme from the target organism, followed by test cultures of the pathogen and sophisticated evaluation in experimental animals. Vast numbers of compounds may be screened in the primaiy in vitro test, with the succeeding screens used to progressively filter out insufficiently active or potentially toxic compounds until a very limited set of compounds is considered to be sufficiently effective to warrant evaluation in a model infection in experimental animals. The second of Ehrlich's methods was the synthesis of chemical variants of a compound exhibiting an interesting but not optimal level of activity. The new compounds were examined for increased activity or for improvements in some other property, such as reduced toxicity. Any improvement found was used as a guide to further synthesis, eventually arriving by a series of steps at the best possible compound. These methods are now so well accepted that their novelty in Ehrlich's day can easily be forgotten. They depend on the thesis that a useful dmg possesses an ideal combination of structural features which cannot be predicted at the outset. A compound approximating this ideal will show some degree of activity and can therefore act as a 'lead' towards the best attainable structure. According to Ehrlich, a chemotherapeutic substance has two functional features, the 'haptophore' or binding group which enables the compound to attach itself to the cell receptors, and the 'toxophore' or toxic group which brings about an adverse effect on the cell. This idea has had a continuing influence in subsequent years. In cancer chemotherapy it has frequently been used in attempts to bring about the specific concentration of toxic agents or antimetabolites in tumour cells. In antimicrobial research it has helped to explain some features of the biochemical action of antimicrobial compounds. Ehrlich also recognized that compounds acting on microbial infection need not necessaiily kill the invading organism. It was, he suggested, sufficient to prevent substantial multiplication of the infectious agent, since the normal body defences, antibodies and phagocytes, would cope with foreign organisms provided that their numbers were not overwhelming. Flis views on this topic were based in part on his obseiwation that isolated syphilis-causing spirochetes treated with low concentrations of salvarsan remained motile and were therefore apparently still alive. Nevertheless they were unable to produce an infection when they were injected into an animal body. It is a striking fact that several of today's important antibacterial and antifungal drugs are 'biostatic' rather than 'biocidal' in action. Another feature of Ehrlich's work was his recognition of the possibility that drugs may be activated by metabolism in the body This suggestion was prompted by the observation that the compound atoxyl was active against trypanosomal infections but was inactive against isolated trypanosomes. His explanation was that atoxyl was reduced in the body to the much more toxic /7-aminophenylarsenoxide (Figure 1.1) . Later work showed that atoxyl and other related arsenic acids are not in fact readily reduced to arsenoxides in the body, but local reduction by the parasite remains a possibility. Ehrlich, surprisingly, did not recognize that his own compound salvarsan would undergo metabolic cleavage. In animals it gives rise to the arsenoxide as the first of a series of metabolites. This compound eventually was introduced into medicine in 1932 under the name Mapharsen (Figure 1 .1); its toxcity is rather high, but it has sufficient selectivity to give it useful chemotherapeutic properties. Other examples of activation through metabolism have been discovered in more recent times; for example, the conversion of the antimalarial 'prodrug' proguanil to the active cycloguanil in the liver and the metabolism of antiviral nucleosides to the inhibitory triphosphate derivatives. Of course, it later emerged that metabolism in the body or in the infecting micro-organism could also result in the inactivation of drags. Ehrlich also drew attention to the problem of resistance of micro-organisms towards chemotherapeutic compounds. He noticed it in the treatment of trypanosomes with parafuchsin and later with trypan red and atoxyl. He found that resistance extended to other compounds chemically related to the original three, but there was no cross-resistance among the groups. In Ehrlich's view this was evidence that each of these compounds was affecting a separate receptor. Independent resistance to different drugs later became a commonplace in antimicrobial therapy. Ehrlich's view of the nature of resistance is also interesting. He found that trypanosomes resistant to trypan red absorbed less of the compound than sensitive strains, and he postulated that the receptors in resistant cells had a diminished affinity for the dye. This mechanism corresponds to one of the currently accepted types of resistance in micro-organisms (Chapter 9) in which mutations affecting the target protein reduce or eliminate drug binding to the target. Several useful antimicrobial dmgs appeared in later years as an extension of Ehrlich's work. The most notable (Figure 1 .2) are suramin, developed from trypan red, and mepacrine (also known as quinacrine or atebrin) developed indirectly from methylene blue (Figure 1.2) . Suramin, introduced in 1920, is a colorless compound with useful activity against human trypanosomiasis. Its particular value lay in its relative safety compared with other antimicrobial dmgs of the period. It was the first useful antimicrobial drug without a toxic metal atom, and the ratio of the dose required to produce toxic symptoms to that needed for a curative effect is vastly higher than with any of the arsenicals. Suramin is remarkably persistent, a single dose giving protection for more than a month. Mepacrine, first marketed in 1933, was an antimalarial agent of immense value in the Second World War. It was supplanted by other compounds partly because it caused a yellow discoloration of the skin. Besides these obvious descendants from Elhrlich's work, the whole field of drug therapy is pemieated by his ideas, and many other important compounds can be traced directly or indirectly to the influence of his thought. In spite of the successes achieved in the treatment of protozoal diseases and the spirochetal disease syphilis, the therapy of bacterial infections remained for many years an elusive and apparently unattainable goal. Ehrlich himself, in collaboration with Bechtold, made a series of phenols which showed much higher antibacterial potency than the simple phenols originally used as disinfectants. These compounds, however, had no effect on bacterial infections in animals. Other attempts were equally unsuccessful and no practical progress was made until 1935, when Domagk reported the activity of prontosil ruhrum (Figure 4 .1) against infections in animals. The discovery occun'ed in the course of a widespread research programme on the therapeutic use of dyestuffs, apparently inspired by Ehrlich's ideas. Trefouel showed that prontosil rubrum is broken down in the body, giving sulfanilamide (Figure 4.1) , which was in fact the effective antibacterial agent. The sulfonamides might have been developed and used more widely if penicillin and other antibiotics had not followed on so speedily. In fact, relatively few wholly synthetic compounds have achieved success against the common bacterial infections mainly because effective synthetic compounds have been difficult to find. After some 60 years of effort, the synthetic antibacterial compounds in current use include, in addition to a few sulfonamides, several drugs for the treatment of tuberculosis, the quinolones, trimethoprim, certain imidazoles such as metronidazole, nitrofurans such as nitrofurantoin, and most recently the oxazolidinone, linezolid. There are also numerous semisynthetic derivatives of naturally occurring antibacterial antibiotics, including P~lactams, aminoglycosides, macrolides, streptogramins and glycopeptides. For several years after treatment was available for streptococcal and staphylococcal infections, the mycobacterial infections that cause tuberculosis and leprosy remained untreatable by chemotherapy. The first success came with the antibiotic streptomycin, which remains an optional part of the standard treatment for tuberculosis. Later, several chemically unrelated synthetic agents were also found to be effective against this disease. The best of these are isonicotinyl hydrazide (isoniazid), ethambutol and pyrazinamide. Another antibiotic, rifampicin (rifampin), is usually included in the current combination therapy for tuberculosis. The synthetic compound, 4,4'-diaminodiphenylsulfoiie, is regularly used in the treatment of leprosy. Ever since bacteria have been cultivated on solid media, contaminant organisms have occasionally appeared on the plate. Sometimes this foreign colony would be surrounded by an area in which bacterial growth was suppressed. Usually this was regarded as a mere technical nuisance, but in 1928, observing such an effect with the mold PeniciUimn notatum on a plate seeded with staphylococci, Alexander Fleming was struck by its potential importance. He showed that the mold produced a freely diffusible substance highly active against Gram-positive bacteria and apparently of low toxicity to animals. He named it penicillin. It was, however, unstable and early attempts to extract it failed, so Fleming's obser\'ation lay neglected until 1939. By then the success of the sulfonamides had stimulated a renewed interest in the chemotherapy of bacterial infections. The search for other antibacterial agents now seemed a promising and exciting project, and Howard Florey and Ernst Chain selected Fleming's penicillin for re-examination. They succeeded in isolating an impure but highly active solid preparation and published their results in 1940. Evidence of its great clinical usefulness in patients followed in 1941. Because of the extraordinary antibacterial potency of penicillin and its minimal toxicity to patients, it was apparent that a compound of revolutionary importance in medicine had been discovered. Making it generally available for medical use, however, presented formidable problems both in research and in large-scale production, especially under conditions of wartime stringency. Eventually perhaps the biggest chemical and biological joint research programme ever mounted was undertaken, involving 39 laboratories in Britain and the United States. It was an untidy operation with much duplication and overlapping of work, but it culminated in the isolation of pure penicillin, the determination of its structure, and the establishment of the method for its production on a large scale. The obstacles overcome in this research were enormous. They arose mainly from the very low concentrations of penicillin in the original mold cultures and from the marked chemical instability of the product. In the course of this work the concentration of penicillin in mold culture fluids was increased 1000-fold by the isolation of improved variants of PeniciUum notatum using selection and mutation methods and by improved conditions of culture. This tremendous improvement in yield was decisive in making large-scale production practicable and ultimately cheap. The success of penicillin quickly diverted a great deal of scientific effort towards the search for other antibiotics. The most prominent name in this development was that of Selman Waksman, who began an intensive search for antibiotics in micro-organisms isolated from soil samples obtained in many parts of the world. Waksman's first success was streptomycin, and other antibiotics soon followed. Waksman's technique of screening soil organisms for antibiotics was immediately copied in many other laboratories. Organisms of all kinds were examined and hundreds of thousands of cultures were tested. Further successes came quickly. Out of all this research, several thousand named antibiotics have been listed. Most of them, however, have adverse properties that prevent their development as drugs. Perhaps 50 have had some sort of clinical use and only a few of these are regularly employed in the therapy of infectious disease. However, among this select group and their semisynthetic variants are compounds of such excellent qualities that treatment is now available for most of the bacterial infections known to occur in humans, although as we have seen, resistance increasingly threatens the efficacy of drug therapy. Following the wave of discovery of novel classes of antibiotics in the 1940s and 1950s, research focused largely on taking antibiotics of proven worth and subjecting them to chemical modification in order to extend their antibacterial spectrum, to combat resistance and to improve their acceptability to patients. Recently, however, the pressure of increasing drug resistance has renewed efforts to discover novel chemical classes of both naturally occurring and synthetic antibacterial compounds. The diversity of fungal pathogens which attack man and his domesticated animals is considerably smaller than that of bacteria. Nevertheless, fungi cause infections ranging from the trivial and inconvenient to those resulting in major illness and death. Fungal infections have assumed greater importance in recent years because of the increased number of medical conditions in which host immunity is compromised. Fungi as eukaryotes have much more biochemistry in common with mammalian cells than bacteria do and therefore pose a serious challenge to chemotherapy. Specificity of action is more difficult to achieve. Few antibiotics are useful against fungal infections, and attention has concentrated on devising synthetic agents. Some advantage has been taken of the progress in producing compounds for the treatment of fungal infections of plants to develop from them reasonably safe and effective drugs for human fungal infections. Elnoniious strides have been made in the control of viral infections through the use of vaccines. Smallpox has been eradicated throughout the world. In the developed countries at least, the seasonal epidemics of poliomyelitis that were the cause of so much fear and suffering 50 years ago have disappeared. But despite these and other vaccine-based successes against viral infections, not all such infections can be so effectively controlled by mass vaccination programmes. The bewildering diversity of common cold viruses, the evershifting antigenic profiles of influenza viruses and the insidious nature of the viras that leads to AIDS are just three examples of diseases that may not yield readily to the vaccine approach. Attention is therefore focused on finding drags that specifically arrest or prevent viral 1.3 Reasons for studying the biochemistry and molecular biology of antimicrobial compounds infection, a fomiidable cliallenge since vimses partially parasitize the biochemistry of the host cells. Nevertheless, considerable success has been achieved in devising effective drugs against several viruses, including HIV, herpes and cytomegalo-viruses and even against influenza viruses. Recombinant forms of the naturally occuning antiviral protein interferon~a (IFN-a) , have a useful role in combating the viruses which cause the liver infections hepatitis B and C. After the Second World War, several valuable new drags were introduced in the fight against malaria, including chloroquine, proguanil and pyrimethamine. For several years these drags were extremely effective for both the prevention and treatment of malaria. However, by the time of the outbreak of the war in Vietnam in the 1960s it had become clear that, like bacteria, the malaiial parasites were adept at finding ways to resist drug therapy. The US government then launched a massive screening project to discover new antimalarial agents. Two compounds, mefloquine and halofantriiie, resulted from this effort and ai^e still in use today. Nevertheless, the development of resistance to these drugs seems inevitable and the search for new antimalarial drugs continues. Several compounds currently offer real promise: the naturally occuning compound, artemisinin and its semisynthetic derivatives, and the synthetic compound, atovaquone. The treatment of other serious protozoal infections, such as the African and South American forms of trypanosomiasis remains relatively primitive. The arsenical melarsoprol is still used for African trypanosomiasis (sleeping sickness), although the less toxic difluorodimethyi ornithine is increasingly seen as the drug of choice. South American trypanosomiasis, or Chagas' disease, is still very difficult to treat successfully; control of the insect vector, the so-called kissing bug which infests poor-quality housing, is very effective. The only useful drugs against leishmaniasis are such venerable compounds as sodium antimony gluconate and pentamidine, neither of which is ideal. Unfortunately, the parasitic diseases of the developing world do not present the major pharmaceutical companies with attractive commercial opportunities, and re-search into the treatment of these diseases is relatively neglected. K 9 %^C^ ^%J' a a ^ 9 %flV 5 ^%